Sign In

Nikola Kaludov

Scientist/Entrepreneur

Professional Background

Nikola Kaludov is a distinguished scientist and entrepreneur whose remarkable career bridges the fields of biology, physics, and chemistry. With a profound commitment to innovation in drug discovery and development, Nikola has utilized big data and advanced methodologies to revolutionize the biotechnology landscape. His extensive experience encompasses the development of chromatography methods for the purification of proteins and viruses, as well as creating robust cell-based and molecular/biochemical assays. A prominent figure in the field, Nikola's work has significantly contributed to pre-clinical drug and medical device development, underpinned by his expert project management skills.

One of Nikola's most notable achievements is transforming two biotechnology research platforms into successful product pipelines. This effort culminated in taking a groundbreaking product through pre-clinical development, leading to an FDA investigational new drug submission. His patented chromatography purification technique for adeno-associated viruses has been licensed to Spark Therapeutics, playing a pivotal role in producing Luxturna™, the first gene therapy approved in the United States designed to cure inherited blindness.

Currently, Nikola serves as the co-founder of AliquantumRx Inc., a therapeutics start-up dedicated to repositioning drugs for malaria prophylaxis. This initiative stems from years of collaboration with Dr. David Sullivan from the Johns Hopkins Malaria Institute dating back to 2011. Additionally, Nikola co-founded Abilis Life Sciences Inc., an innovative start-up that harnesses modern metabolomics and biomarker analytics to enhance disease diagnosis through non-invasive approaches. His entrepreneurial spirit and scientific expertise continue to drive forward-thinking solutions in healthcare.

Education and Achievements

Nikola's academic journey laid a strong foundation for his illustrious career in science and biotechnology. He earned his PhD in Biochemistry and Molecular Biology from Florida State University, where he honed his research skills and deepened his understanding of complex biological processes. Prior to this, he obtained a Master's degree in Biotechnology from Sofia University St. Kliment Ohridski. This diverse educational background has equipped Nikola with a unique perspective, enabling him to approach challenges with creativity and scientific rigor.

Throughout his career, Nikola has been associated with several prominent organizations, where he has held key roles that showcase his leadership and scientific acumen. His professional journey includes serving as the Co-Founder and President of AliquantumRx Inc., and previously as the Co-Founder and COO of Abilis Life Sciences Inc. Nikola has also contributed to scientific operations in various capacities, including serving as the Director of Scientific Operations at ImQuest Biosciences Inc. and as a Senior Scientist at Apollo Life Sciences. His contract work with the NIH and experience as a Visiting Fellow at GTTB further underscores his dedication to advancing scientific knowledge.

Achievements

Nikola Kaludov’s career is marked by an impressive array of accomplishments that underscore his expertise and impact in the field. A few of his key achievements include:

  • Patented Chromatography Method: Nikola's innovative approach to chromatography has led to the development of a patented method for the purification of adeno-associated viruses, which has been licensed to Spark Therapeutics. This method has been integral to the production of Luxturna™, a groundbreaking gene therapy that has revolutionized treatment for inherited blindness.
  • FDA Investigational New Drug Submission: Successfully guiding a product through pre-clinical development to secure FDA investigational new drug submission is a testament to Nikola's strategic insight and deep understanding of both regulatory pathways and scientific research.
  • Start-Up Leadership: As co-founder of both AliquantumRx Inc. and Abilis Life Sciences Inc., Nikola is at the forefront of emerging therapeutic solutions, focusing on drug repositioning and advanced diagnostics through metabolomics and biomarker analytics. This entrepreneurial journey illustrates Nikola's commitment to innovative healthcare solutions.
  • Collaboration with Renowned Institutions: His ongoing collaboration with the Johns Hopkins Malaria Institute since 2011 highlights Nikola's dedication to addressing pressing health challenges, particularly in the realm of infectious diseases.

In summary, Nikola Kaludov exemplifies what it means to be a leader in the biotechnology field. His journey as a scientist and entrepreneur showcases a commitment to advancing healthcare through innovation, research, and a collaborative approach. With a rich educational background and a portfolio of significant achievements, Nikola continues to make strides that enhance our understanding and treatment of complex diseases. His holistic approach to bioinnovation not only positions him at the cutting edge of science but also reflects his vision of a healthier future for all.

Related Questions

How did Nikola Kaludov transform his biotechnology research platforms into successful product pipelines?
What inspired Nikola Kaludov to develop a patented chromatography purification method for adeno-associated viruses?
In what ways has Nikola Kaludov's educational background influenced his entrepreneurial ventures in pharmaceuticals?
How does Nikola Kaludov approach collaboration with research institutions like the Johns Hopkins Malaria Institute?
What are Nikola Kaludov's plans for the future of AliquantumRx Inc. and its malaria prophylactic drug?
Nikola Kaludov
Add to my network

Location

Washington, District of Columbia, United States